Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
01 2022
Historique:
received: 28 09 2021
accepted: 22 12 2021
pubmed: 2 1 2022
medline: 15 1 2022
entrez: 1 1 2022
Statut: ppublish

Résumé

Many SARS-CoV-2 antibody detection assays have been developed but their differential performance is not well described. In this study we compared an in-house (KWTRP) ELISA which has been used extensively to estimate seroprevalence in the Kenyan population with WANTAI, an ELISA which has been approved for widespread use by the WHO. Using a wide variety of sample sets including pre-pandemic samples (negative gold standard), SARS-CoV-2 PCR positive samples (positive gold standard) and COVID-19 test samples from different periods (unknowns), we compared performance characteristics of the two assays. The overall concordance between WANTAI and KWTRP was 0.97 (95% CI, 0.95-0.98). For WANTAI and KWTRP, sensitivity was 0.95 (95% CI 0.90-0.98) and 0.93 (95% CI 0.87-0.96), respectively. Specificity for WANTAI was 0.98 (95% CI, 0.96-0.99) and 0.99 (95% CI 0.96-1.00) while KWTRP specificity was 0.99 (95% CI, 0.98-1.00) and 1.00 using pre-pandemic blood donors and pre-pandemic malaria cross-sectional survey samples respectively. Both assays show excellent characteristics to detect SARS-CoV-2 antibodies.

Identifiants

pubmed: 34973474
pii: S1386-6532(21)00328-0
doi: 10.1016/j.jcv.2021.105061
pmc: PMC8711170
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0
Spike Glycoprotein, Coronavirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105061

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005293/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

James Nyagwange (J)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya. Electronic address: jnyagwange@kemri-wellcome.org.

Bernadette Kutima (B)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Kennedy Mwai (K)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, 27 St Andrews Road, Parktown 2193, Johannesburg, South Africa.

Henry K Karanja (HK)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

John N Gitonga (JN)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Daisy Mugo (D)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Sophie Uyoga (S)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

James Tuju (J)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Lynette I Ochola-Oyier (LI)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Francis Ndungu (F)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Philip Bejon (P)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya; Nuffield Department of Medicine, Oxford University, OX3 7BN, Oxford, United Kingdom.

Ambrose Agweyu (A)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya.

Ifedayo M O Adetifa (IMO)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT, Keppel Street, London, United Kingdom.

J Anthony G Scott (JAG)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT, Keppel Street, London, United Kingdom.

George M Warimwe (GM)

KEMRI-Wellcome Trust Research Programme, PO Box 230, Kilifi, Kenya; Nuffield Department of Medicine, Oxford University, OX3 7BN, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH